MX2023012557A - Composicion que comprende un anticuerpo ige. - Google Patents

Composicion que comprende un anticuerpo ige.

Info

Publication number
MX2023012557A
MX2023012557A MX2023012557A MX2023012557A MX2023012557A MX 2023012557 A MX2023012557 A MX 2023012557A MX 2023012557 A MX2023012557 A MX 2023012557A MX 2023012557 A MX2023012557 A MX 2023012557A MX 2023012557 A MX2023012557 A MX 2023012557A
Authority
MX
Mexico
Prior art keywords
composition
ige antibody
fra
ige
antibody
Prior art date
Application number
MX2023012557A
Other languages
English (en)
Spanish (es)
Inventor
James Spicer
Sophia Karagiannis
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/060749 external-priority patent/WO2021214329A1/en
Priority claimed from GBGB2109550.0A external-priority patent/GB202109550D0/en
Application filed by King S College London filed Critical King S College London
Publication of MX2023012557A publication Critical patent/MX2023012557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2023012557A 2021-04-23 2022-04-22 Composicion que comprende un anticuerpo ige. MX2023012557A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2021/060749 WO2021214329A1 (en) 2020-04-24 2021-04-23 Composition comprising an ige antibody
GBGB2109550.0A GB202109550D0 (en) 2021-07-01 2021-07-01 Composition
PCT/EP2022/060693 WO2022223784A1 (en) 2021-04-23 2022-04-22 Composition comprising an ige antibody

Publications (1)

Publication Number Publication Date
MX2023012557A true MX2023012557A (es) 2023-11-08

Family

ID=81750377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012557A MX2023012557A (es) 2021-04-23 2022-04-22 Composicion que comprende un anticuerpo ige.

Country Status (10)

Country Link
US (1) US20240190955A1 (https=)
EP (1) EP4326770A1 (https=)
JP (1) JP2024514935A (https=)
KR (1) KR20240001136A (https=)
AU (1) AU2022263376A1 (https=)
BR (1) BR112023021873A2 (https=)
CA (1) CA3215850A1 (https=)
MX (1) MX2023012557A (https=)
WO (1) WO2022223784A1 (https=)
ZA (1) ZA202309456B (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
CA2848842C (en) 2011-10-04 2020-09-29 King's College London Ige anti -hmw-maa antibody
RU2019141270A (ru) 2017-05-16 2021-06-16 Иммуноджен, Инк. Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
GB202006093D0 (en) * 2020-04-24 2020-06-10 King S College London Composition

Also Published As

Publication number Publication date
EP4326770A1 (en) 2024-02-28
AU2022263376A9 (en) 2023-11-30
CA3215850A1 (en) 2022-10-27
WO2022223784A1 (en) 2022-10-27
AU2022263376A1 (en) 2023-11-23
JP2024514935A (ja) 2024-04-03
ZA202309456B (en) 2025-03-26
BR112023021873A2 (pt) 2023-12-19
US20240190955A1 (en) 2024-06-13
KR20240001136A (ko) 2024-01-03

Similar Documents

Publication Publication Date Title
MX2019001469A (es) Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
AR120563A1 (es) Receptores de antígeno quimérico cd19 y cd22 y sus usos
CL2021000736A1 (es) Receptor de antígeno quimérico.
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
BR112019001570A2 (pt) terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
PE20210633A1 (es) CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESION DE PNPLA3 Y METODOS DE USO DE LOS MISMOS
PE20211225A1 (es) Constructos de arni para inhibir la expresion de pnpla3
MX2016013239A (es) Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19.
BR112015022776A2 (pt) estruturas de sola e artigos de calçado tendo elementos de entressola leve com elementos de proteção
MX381600B (es) Composicion que comprende un agente de control biologico y un fungicida.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2021010347A2 (es) Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
MX2020002243A (es) Anticuerpos utiles en diagnosis de cancer.
UY38800A (es) Receptor de antígeno quimérico (car) anti-hk2
CO2023015212A2 (es) Receptores quiméricos dirigidos a adgre2 y/o clec12a y usos de estos
BRPI0606432A2 (pt) anticorpos monoclonais contra angptl4
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.
CL2024003668A1 (es) Anticuerpo anti-fcrn o fragmento de unión a antígeno del mismo con estabilidad mejorada.
CL2023001509A1 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos
CO2024001251A2 (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.